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Abstract (149 words)
Opioid-induced constipation has a negative impact on quality of life for patients

3

with chronic pain and can affect more than a third of patients. A related but separate

4

entity is postoperative ileus, which is an abnormal pattern of gastrointestinal motility

5

after surgery. Non-selective μ-opioid receptor antagonists reverse constipation and

6

opioid-induced ileus but cross the blood-brain barrier and may reverse analgesia.

7

Peripherally acting μ-opioid receptor antagonists target the μ-opioid receptor without

8

reversing analgesia. Three such agents are FDA-approved. We reviewed the literature for

9

randomized, controlled trials that studied the efficacy of alvimopan, methylnaltrexone,

10

and naloxegol in treating either opioid-induced constipation or postoperative ileus.

11

Peripherally acting μ-opioid receptor antagonists may be effective in treating both opioid-

12

induced bowel dysfunction and postoperative ileus but definitive conclusions are not

13

possible due to study inconsistency and the relatively low quality of evidence.

14

Comparisons of agents are difficult due to heterogeneous endpoints and no head-to-head

15

studies.

4
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Introduction
Despite recent focus on the opioid epidemic millions of patients rely on opioids to

18

treat their chronic pain.1 Opioid-related adverse drug effects are common, especially

19

opioid-induced bowel dysfunction (OIBD), which is a spectrum of symptoms including

20

dry mouth, nausea, vomiting, gastric stasis, bloating, abdominal pain, and opioid-induced

21

constipation (OIC).2 OIC is especially prevalent, affecting up to 41% of patients taking

22

long-term opioids.3 A working group of experts recently proposed that OIC be defined as

23

a change when initiating opioid therapy from baseline bowel habits that is characterized

24

by any of the following: reduced bowel movement frequency; development or worsening

25

of straining to pass bowel movements; a sense of incomplete rectal evacuation; or harder

26

stool consistency.4

27

Postoperative ileus (POI) is a related but distinct entity from OIC that also

28

involves loss of forward propulsive motion of the gut but in the perioperative setting. A

29

standard POI definition does not exist in the literature, but the authors of one review

30

suggest that it is “an abnormal pattern of gastrointestinal motility, most frequently

31

occurring after abdominal surgery” and encompasses the “interval from surgery until

32

passage of flatus/stool and tolerance of an oral diet.”5 POI has a multifactorial etiology

33

that is shared with OIC, including the surgical stress response,6,7 the inflammatory

34

response that accompanies bowel manipulation,6,7,8 and opioids that are both

35

endogenously released by the GI tract7 and given by clinicians for intra- and

36

postoperative analgesia.9 Most importantly, POI can be a driver of poor patient

37

satisfaction, increase hospital length of stay, and increase overall hospital costs.10

5
38

Throughout the hospital physicians will likely encounter patients with one or both

39

of these conditions and need a good working knowledge of the basic mechanisms and

40

therapeutic options that are available to treat these relatively common pathophysiologic

41

states.

42

Conventional therapies, including fiber, opioid rotation, stool softeners, and

43

laxatives, have limited data to support their use in OIC.11 They may be used initially with

44

relatively low risk and minimal cost but are unlikely to effectively treat the symptoms

45

alone. Non-specific opioid antagonists can reverse OIC and POI but may reverse

46

analgesia as well.12 Drugs that specifically block the µ-opioid receptor outside of the

47

central nervous system, collectively known as peripherally acting µ-opioid receptor

48

(PAM-OR) antagonists, have been developed as a possible solution to this problem.

49

PAM-OR antagonists specifically target the µ-opioid receptor in the peripheral nervous

50

system and treat one of the major underlying mechanisms of both OIC and POI. In the

51

United States three such drugs are approved for one of these two indications: alvimopan,

52

methylnaltrexone, and naloxegol.

53

Currently, alvimopan has approval from the Food and Drug Administration (FDA

54

as a “peripherally acting µ-opioid receptor antagonist indicated to accelerate the time to

55

upper and lower gastrointestinal recovery following partial large or small bowel resection

56

surgery with primary anastomosis.”13 Methylnaltrexone was first approved as a

57

subcutaneous injection “for the treatment of opioid-induced constipation in patients with

58

advanced illness who are receiving palliative care, when response to laxative therapy has

59

not been sufficient”14 and very recently was approved in the oral formulation for patients

60

with chronic non-cancer pain and OIC.15 The most recent addition to the PAM-OR

6
61

antagonists, naloxegol, has been in clinical use since its approval in 2014 as “an opioid

62

antagonist indicated for the treatment of opioid-induced constipation (OIC) in adult

63

patients with chronic non-cancer pain.”16 Several randomized trials involving PAM-OR

64

antagonists have recently been published17,18; in addition, previous reviews have focused

65

solely on a single agent19,20 or either OIC21 or POI22 but not both. Therefore, an update

66

that discusses strengths and limitations of the evidence is warranted. We conducted a

67

systematic review for randomized, placebo-controlled trials that compared alvimopan,

68

methylnaltrexone, and naloxegol to placebo and had efficacy as the primary endpoint.

69

The subsequent discussion will focus on the evidence for these PAM-OR antagonists in

70

treating OIC and POI.

71
72
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Methods
We conducted the review protocol using the Preferred Reporting Items for

75

Systematic Reviews and Meta-Analyses (PRISMA) guidelines.23 During the months of

76

April and May 2016 and again in February 2017, we conducted searches using PubMed

77

and Scopus databases looking for randomized, placebo-controlled trials that studied the

78

efficacy of alvimopan, methylnaltrexone, or naloxegol in patients with OIC or

79

postoperative ileus. The last date searched was February 3, 2017. There were no date

80

limitations placed on the searches in either database. We used the following search

81

protocol in PubMed: (((“alvimopan”[Supplementary Concept] OR “alvimopan”[All

82

Fields]) OR (“methylnaltrexone”[Supplementary Concept] OR “methylnaltrexone”[All

83

Fields]) OR (“naloxegol”[Supplementary Concept] OR “naloxegol”[All Fields])) OR

84

“peripheral opioid antagonist”[All Fields] OR “peripherally acting opioid antagonist”[All

85

Fields] OR (peripheral[All Fields] AND mu[All Fields] AND antagonist[All Fields]) OR

86

(peripheral[All Fields] AND mu[All Fields] AND (“narcotic

87

antagonists”[Pharmacological Action] OR “narcotic antagonists”[MeSH Terms] OR

88

(“narcotic”[All Fields] AND “antagonists”[All Fields]) OR “narcotic antagonists”[All

89

Fields] OR (“opioid”[All Fields] AND “antagonist”[All Fields]) OR “opioid

90

antagonist”[All Fields])) OR “opioid antagonist”[All Fields]) AND (“postoperative ileus”

91

OR “opioid-induced bowel dysfunction”[All Fields] OR “opioid-induced

92

constipation”[All Fields]).

93

Our search protocol for Scopus included the following: ( ALL ( alvimopan ) OR

94

ALL ( methylnaltrexone ) OR ALL ( naloxegol ) OR ALL ( peripheral opioid

95

antagonist ) OR ALL ( peripherally acting opioid antagonist ) OR ALL ( opioid

8
96

antagonist ) AND ALL ( opioid-induced bowel dysfunction ) OR ALL ( opioid-induced

97

constipation ) OR ALL ( postoperative ileus ) ) AND DOCTYPE ( ar ) AND ( LIMIT-

98

TO(LANGUAGE,”English” ) ).

99
100
101

Inclusion Criteria
Studies that were written in English involving clinical patients who had OIC and

102

were being given either a PAM-OR antagonist or placebo or were given a PAM-OR

103

antagonist or placebo for the purpose of treating or preventing POI were included.

104
105
106

Exclusion Criteria
Studies that examined a PAM-OR antagonist in the setting of experimentally

107

induced OIC (giving healthy volunteers codeine followed by a PAM-OR antagonist, for

108

example) were extracted but included in a separate table and not included in the formal

109

review. Studies that were prospective but did not include a placebo group were excluded,

110

as were studies in which patients were not randomized. Also excluded were post-hoc or

111

subset analyses of clinical trials that had been previously published. When applicable,

112

only the blinded portion of a study was reviewed and analyzed.

113
114
115

Review Protocol and Evidence Grading
Evidence quality was assessed using the Grades of Recommendation, Assessment,

116

Development, and Evaluation (GRADE) approach (see Tables 1 and 2).24 Using this

117

approach, studies are classified as high, moderate, low, or very low quality of evidence.

9
118

All articles were first reviewed independently by ES and AG and assessed for

119

inclusion in the review. If the determination could not be made from reading the article

120

title, the abstract was reviewed, and if ambiguity remained after that, the full article was

121

subsequently downloaded and reviewed. Reference lists from screened articles were

122

searched as well. Discrepancies were resolved by discussion between ES and AG.

123

Articles that met all inclusion criteria but studied OIC treatment in healthy volunteers

124

were not included in the formal review but are shown separately in Table 1.

125
126
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Results

128

Study Selection

129

Initial search of the literature yielded 1,314 articles (Figure 1). Screening of

130

reference lists yielded two additional studies.25,26 One additional study that was initially

131

excluded because it referred to alvimopan as ADL 8-2698, its investigational name, was

132

later included in the review after confirming that it did in fact study alvimopan (Figure

133

1).27 Because of the overlap between PubMed and Scopus databases, there were 158

134

duplicates. Reasons for exclusion are shown in Figure 1. The two most common reasons

135

for exclusion were that PAM-OR antagonists were not studied (n=588), which primarily

136

applied to Scopus articles, and that the studies were not randomized, controlled trials

137

(RCTs; n=459). A total of 23 studies were included in the final review. The four RCTs

138

that enrolled healthy volunteers were grouped separately and are shown in Table 1.28-31

139
140

Opioid-Induced Bowel Dysfunction Studies in Healthy Volunteers

141

Four Phase 1 studies enrolled healthy volunteers and administered a µ-opioid

142

agonist to induce delay in gut transit and then administered a PAM-OR antagonist to

143

evaluate its effects on gut transit time compared to placebo (Table 1).28-31 In the single

144

study on alvimopan,30 12 mg was given along with codeine 30 mg four times a day and

145

alvimopan reversed the codeine-induced delay in gut transit and improved gut transit in

146

patients not given codeine as well.

147

In one of the studies that enrolled healthy volunteers who were given morphine

148

and then randomly assigned to one of two doses of subcutaneous methylnaltrexone or

149

placebo,29 both the 0.1 and 0.3 mg/kg doses reversed morphine-induced delay in gut

11
150

transit time. Wong et al, however, did not find any difference between subcutaneous

151

methylnaltrexone 0.3 mg/kg and placebo in reducing the codeine-induced delay in gut

152

transit.31 Yuan et al gave healthy volunteers intravenous methylnaltrexone 0.45 mg/kg

153

after giving them morphine and found that methylnaltrexone prevented 97% of

154

morphine-induced delay in gut transit time.28

155
156
157

Opioid-Induced Constipation Studies
A total of 14 RCTs that studied PAM-OR antagonists in the setting of OIC were

158

included in the review (Table 2). All alvimopan studies included patients with non-cancer

159

pain who were given oral alvimopan in either a 0.5- or 1-mg dose. The primary outcome

160

for two studies was the percentage of patients with at least three spontaneous bowel

161

movements (SBMs) per week.32,33 One study’s primary outcome was the mean frequency

162

of weekly SBMs34 and in another it was the percentage of patients that had a BM within

163

eight hours.35 When analyzing the primary outcome of the four studies on alvimopan,

164

three showed a positive result for the alvimopan group32,34,35 and one showed no

165

difference.33 Study quality was low for all four studies.

166

The effects of alvimopan on µ-opioid receptors in the central nervous system

167

were minimal. Three alvimopan studies reported no differences in pain scores or opioid

168

consumption between study groups,32,33,34 while one study described two patients in the

169

1-mg alvimopan group who had increases in pain but no difference between groups

170

receiving the 0.5-mg dose.35

171
172

There were seven studies on methylnaltrexone for OIC.17,18,36-40 Four studies
included patients with non-cancer pain only,18,36,39,40 while the other three enrolled

12
173

patients with both cancer and non-cancer pain.17,37,38 The selected dose for studies with

174

subcutaneous methylnaltrexone was 12 mg in two studies,39,40 8 or 12 mg in one study,17

175

0.15 mg/kg in one study, 0.15 or 0.3 mg/kg in one study,38 and up to 0.365 mg/kg in the

176

study that used intravenous methylnaltrexone.36 The single study of oral

177

methylnaltrexone included doses of 150, 300, and 450 mg.18 The primary outcome was

178

positive in all seven studies. In five studies, the primary outcome was achievement of a

179

spontaneous bowel movement (SBM) within 4 hours of receiving the study drug17,37-383940

180

Another study had no primary endpoint but reported that laxation occurred within one

181

minute of initiating methylnaltrexone intravenous infusion in 10 of 11 patients.36 In the

182

single study of the oral formulation, the primary endpoint was the percentage of patients

183

with a mean number of dosing days resulting in a SBM within four hours of dosing.

184

Although this endpoint was greater in both 300- and 450-mg groups, it was lower than

185

the response rate for the subcutaneous formulation.18 The 450-mg dose had highest

186

efficacy without increasing adverse events. Study quality was moderate for two

187

studies,17,18 low for three studies,37-3839 and very low for two studies.36,40

188

In five of the studies, analgesia was preserved based on no differences in pain

189

scores, opioid consumption, or both between treatment groups.17,37-383940 For oral

190

methylnaltrexone, pain scores did not change from baseline.18 In the remaining study,

191

pain and opioid use were not assessed but patients reported no change in subjective

192

withdrawal symptoms.36 In the largest study by Michna et al,39 rescue laxatives were used

193

by 61.7% of the placebo group versus 38.7% in the daily dosing group and 41.7% in the

194

every-other-day dosing group.
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195

There were two published articles for naloxegol, one of which described a study

196

involving patients with cancer and non-cancer pain41 while the other studied only non-

197

cancer pain and consisted of two smaller trials.42 Both studies had positive outcomes for

198

the primary outcome which was a greater number of SBMs per week for both 25- and 50-

199

mg doses in the article by Webster et al41 and accelerated time to first rescue-free bowel

200

movement (RFBM) for 25 mg in both trials for Chey et al and 12.5 mg in one of two

201

trials.42 Study quality was moderate for one study42 and low for the other.41

202

In both naloxegol studies, analgesia was preserved with no differences in pain

203

scores or opioid consumption existing between study groups. The use of rescue laxatives

204

was high in placebo and treatment groups for the study by Chey et al (72.0, 63.4, and

205

54.7% in study 04 and 70.7, 57.3, and 57.3% in study 05).42 When comparing naloxegol

206

to oral methylnaltrexone, 50% of patients who received 25 mg of naloxegol had a RFBM

207

within six hours of the first dose, compared to approximately 30% of patients who

208

received 450 mg of oral methylnaltrexone.18,41 However, the incidence of GI adverse

209

events was greater for naloxegol than for oral methylnaltrexone.

210
211
212

Postoperative Ileus Studies
A total of 10 studies on POI were included in the review (Table 3). Primary

213

endpoints of the studies varied but most used the achievement of either GI-2 recovery

214

(toleration of solid food and first bowel movement) or GI-3 recovery (toleration of solid

215

food and flatus or first bowel movement). Of the eight studies that examined alvimopan,

216

five enrolled patients who underwent major abdominal surgery,43-47 one included bowel

217

resection,48 one included patients undergoing total abdominal hysterectomy,49 and one

14
218

included radical cystectomy.50 Aside from the study by Taguchi et al,43 which was a

219

Phase I study, four of the other alvimopan studies examined both 6- and 12-mg doses,44-47

220

while the remaining three only used 12 mg.48-50 These doses were three- to six-fold

221

greater than the doses used for OIC. Of note, six alvimopan studies excluded chronic

222

opioid users.43,45,46,47,48,49 Six studies reported positive results for the primary outcome of

223

accelerated GI recovery (flatus, GI-2, or GI-3),43,44,45,48,49,50 while two alvimopan studies

224

found no difference between groups,46,47 although Viscusi et al did report an accelerated

225

time to GI-2 recovery (secondary endpoint) in the alvimopan group for both 6- and 12-

226

mg doses. Study quality was moderate for four studies,45-48 low for two,49,50 and very low

227

for one.43

228

Analgesia was preserved in seven of the studies for all groups,43-50 with the

229

exception of the 6-mg group in one study which demonstrated greater opioid

230

consumption than placebo.44

231

Yu et al51 studied methylnaltrexone intravenously (IV) for POI at both 12- and

232

24-mg doses in two identical, parallel-group studies for patients who underwent

233

segmental colectomy. For the primary endpoint of time until first SBM, they found no

234

difference between groups. They also found no difference among any secondary

235

endpoints. Study quality was moderate. Preservation of analgesia was unclear because the

236

authors did not report pain scores nor opioid consumption, although they stated that

237

“there was no evidence that methylnaltrexone increased the requirement for opioids to

238

relieve postsurgical pain.” Viscusi et al,26 in contrast, studied IV methylnaltrexone in the

239

setting of POI and found that it accelerated time to first SBM; however, this study was

15
240

exploratory with a small sample size (n=65) that was not determined prior to patient

241

enrollment.

242
243
244
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Discussion
This review demonstrates that PAM-OR antagonists may be effective for OIC and

247

POI without reversing opioid-mediated analgesia but study design inconsistency and

248

variable endpoints makes definitive conclusions impossible. PAM-OR antagonists as a

249

class prevent opioid-induced increases in gut transit time in healthy volunteers and

250

provide specific, targeted treatment of OIC and POI that result from a loss of coordinated

251

propulsive action in the gut due to opioids.

252

The studies reviewed ranged from very low to moderate quality according to the

253

GRADE recommendations for rating study quality.24 There is especially a need for

254

comparative studies that directly compare two or more of the three agents studied here.

255

Heterogeneity in endpoints as well as study protocols was a problem throughout the

256

literature.

257

Our results agree with the meta-analysis by Ford et al,21 who found that

258

methylnaltrexone was more effective than placebo in treating OIC. While their analysis

259

included six trials, ours included eight. They also concluded that alvimopan was superior

260

to placebo for OIC and included four trials, as we did. They too noted considerable

261

heterogeneity among studies, more so with methylnaltrexone. Subsequent pooled

262

analyses confirmed the efficacy of methylnaltrexone52,53 and suggested that it may be

263

particularly effective in those patients taking large daily opioid doses. Rauck et al

264

reported that gastrointestinal side effects with oral methylnaltrexone occurred at the same

265

rate as in the placebo group,18 which did not appear to be the case with the subcutaneous

266

formulation.17,39 This should be considered when choosing between the two formulations,

267

although this finding needs additional confirmatory studies.

17
268

Although alvimopan was studied in the setting of OIC, it is approved only for the

269

treatment of POI in hospitalized patients who have undergone partial small or large

270

bowel resection surgery.54 This is reflected by the existence of fewer studies for

271

alvimopan in OIC and the lack of recent, late-phase studies and post-hoc analyses. As

272

stated by Irving et al, “alvimopan was under clinical development for long-term treatment

273

of opioid-induced constipation but this program has been discontinued.”33 Concerns by

274

the Food and Drug Administration over the “imbalance” in the number of cardiovascular

275

events (more myocardial infarctions) in the alvimopan group versus placebo group

276

prompted the discontinuation of the OIC program and limited its approved indication to

277

inpatient use only.55 Positive results in one of the two replicate Phase 3 studies32 but not

278

the other33 speak to the lack of evidence for a specific dose and inconsistent study design

279

between these and an earlier Phase 2 study.34

280

Naloxegol, the newest PAM-OR antagonist in the group, has demonstrated

281

positive results in both studies in this review and agrees with the findings of other

282

reviews.19 Leppart and Woron reported that naloxegol was effective in up to 49% of

283

patients not responsive to standard laxatives and that naloxegol has been shown to be

284

more effective than placebo in patients with OIC and noncancer pain. No studies have

285

been performed in cancer patients.19 The approved dose is 25 mg.16 Comparison of

286

naloxegol to oral methylnaltrexone is difficult because the primary endpoints are not the

287

same from the published studies. However, the available data suggest that while both

288

agents are effective, adverse effects occurred at a greater frequency with naloxegol

289

compared to placebo41,42 while patients who received oral methylnaltrexone had a similar

18
290

rate of adverse effects as the placebo group.18 Although confirmatory studies are needed,

291

this suggests oral methylnaltrexone may have a superior side-effects profile.

292

For POI, the only PAM-OR antagonist FDA-approved for this indication is

293

alvimopan. Heterogeneity in endpoints was a problem throughout the literature with most

294

studies using some composite form of return to GI function. When given preoperatively

295

and continued postoperatively, we found that alvimopan is effective in reducing POI. An

296

important exclusion in many of the studies was opioid use prior to surgery. This could

297

limit the number of patients who can receive alvimopan.

298

Viscusi et al reported that both methylnaltrexone and alvimopan do not cross the

299

blood brain barrier for different reasons: for methylnaltrexone, this is due to its polarity

300

and low lipid solubility that results from the addition of a fourth methyl group to

301

naltrexone, making it a quaternary structure; for alvimopan, this is due its high polarity as

302

a zwitterion.7 Our review included three additional alvimopan studies and one additional

303

methylnaltrexone study not included in theirs. We found no evidence for reversal of

304

opioid-mediated analgesia, although one study did not include any measurements.51

305

Methylnaltrexone studies for POI had conflicting evidence in this review. In the

306

two studies that evaluated it in this context,26,51 the IV formulation was given

307

postoperatively. It should be noted that the study that reported positive results enrolled 65

308

patients, while the study that found no improvement with methylnaltrexone was actually

309

the results of two identical studies with n=515 and n=533.

310

It should be noted that three alvimopan studies45,47,50 and one methylnaltrexone51

311

POI study specified that they did not allow epidural analgesia in the protocols, which is

312

understandable given the existing evidence for epidurals.56 In the other POI studies it was

19
313

not stated whether epidural analgesia was excluded. In a multimodal or enhanced

314

recovery after surgery (ERAS) pathway involving epidural analgesia, the duration of

315

ileus in the placebo group would likely be shorter. Similarly, intravenous lidocaine has

316

been shown to reduce duration of ileus and this was excluded from the studies as well.57

317

Therefore, clinicians should consider this when evaluating the potential improvement in

318

POI duration that a PAM-OR antagonist may produce.

319

Comparative-effectiveness studies in this field are clearly needed. None of the

320

studies included in this review compared one PAM-OR antagonist to another. This makes

321

direct comparisons difficult especially when heterogeneity in endpoints for the individual

322

studies is taken into account. In addition, laxatives were permitted in some studies and

323

not others, further complicating the picture. Although we did not analyze medication cost

324

in this review, these charges as well as insurance coverage are additional considerations

325

that may affect choice of agent.

326

This review has some limitations. We were unable to determine if there were

327

unpublished studies that did not show positive results, and it is possible that some of

328

these stopped prematurely. This may be particularly true with alvimopan, which was

329

studied for OIC and subsequently abandoned for that indication. Second, there may be

330

some studies that were not located through our search protocols. We attempted to

331

minimize this limitation by combining two search databases, using two reviewers, and

332

using as broad of a selection of search terms as feasible. However, studies with different

333

key words or search terms could have been omitted.

334
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Conclusion
In conclusion, PAM-OR antagonists may be effective in both OIC and POI but

337

the inconsistency of study design, study endpoints, and lack of comparative studies limits

338

the strength of our recommendations. Within the class methylnaltrexone has the most

339

consistent evidence, and its oral formulation may be slightly less effective than the

340

subcutaneous formulation but cause fewer gastrointestinal adverse effects. Although

341

naloxegol is more effective than placebo for OIC, it appears to cause more adverse

342

effects than oral methylnaltrexone. Alvimopan is the only FDA-approved and most well-

343

studied agent for POI. Comparative studies are lacking. A multimodal treatment strategy

344

for OIC and POI is recommended for these multifactorial disease states and evaluation of

345

these agents combined with epidural analgesia and intravenous lidocaine is needed.

346

Additional PAM-OR antagonists are currently under development but the potential

347

market for these agents may become smaller as efforts to fight the opioid epidemic

348

intensify.
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